Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Update

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,460,000 shares, a decline of 47.5% from the January 31st total of 2,780,000 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average daily volume of 2,750,000 shares, the short-interest ratio is currently 0.5 days.

Tevogen Bio Trading Up 2.4 %

NASDAQ TVGN traded up $0.03 on Friday, reaching $1.28. 437,963 shares of the company’s stock traded hands, compared to its average volume of 2,919,859. The stock has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.14. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $8.49.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after purchasing an additional 107,566 shares during the period. HGC Investment Management Inc. purchased a new position in Tevogen Bio in the third quarter valued at $82,000. Northern Trust Corp increased its holdings in Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after buying an additional 13,595 shares in the last quarter. XTX Topco Ltd purchased a new position in Tevogen Bio in the fourth quarter valued at $55,000. Finally, Barclays PLC increased its holdings in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after buying an additional 12,847 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.